Hormonal Therapy in Endometriosis and Adenomyosis: Danazol, Aromatase Inhibitors

Simone Ferrero, Fabio Barra
In: Endometriosis and Adenomyosis · 2022 · pp. 557–575 · doi:10.1007/978-3-030-97236-3_42 · W4285178406
book-chapter OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-06 ⓘ

Danazol and aromatase inhibitors treat endometriosis and adenomyosis by reducing estrogen, but both have significant side effects limiting their use.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 ⓘ

This paper is a narrative overview of hormonal therapies with hypoestrogenic mechanisms—specifically danazol and aromatase inhibitors—for endometriosis and adenomyosis, describing evidence from randomized trials for endometriosis-related pain and other study types across disease subtypes. It reports that danazol has shown efficacy for endometriosis pain but is limited by androgenic adverse effects, while aromatase inhibitors can treat forms of endometriosis including ovarian endometrioma and deep-infiltrating disease but are constrained by side effects such as myalgia, arthralgia, and loss of mineral bone density, and adenomyosis evidence is comparatively sparse (including limited/early studies such as danazol-loaded intrauterine devices and only one RCT of aromatase inhibitors). The paper’s caveat is that available adenomyosis data are limited, and its comparisons emphasize safety/tolerability constraints rather than robust head-to-head outcomes across all indications. Relevance to endometriosis: the chapter directly reviews randomized controlled trial evidence for danazol efficacy in endometriosis pain and multiple studies of aromatase inhibitors in endometriosis subtypes, while also noting limited data for adenomyosis; however, its main focus is hormonal therapy options (danazol and aromatase inhibitors) across both conditions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (55)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK